Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis.
Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, Direnzo D, Nanda V, Ye J, Connolly AJ, Schadt EE, Quertermous T, Betancur P, Maegdefessel L, Matic LP, Hedin U, Weissman IL, Leeper NJ. Kojima Y, et al. Nature. 2016 Aug 4;536(7614):86-90. doi: 10.1038/nature18935. Epub 2016 Jul 20. Nature. 2016. PMID: 27437576 Free PMC article.
The Role of Efferocytosis in Atherosclerosis.
Kojima Y, Weissman IL, Leeper NJ. Kojima Y, et al. Circulation. 2017 Jan 31;135(5):476-489. doi: 10.1161/CIRCULATIONAHA.116.025684. Circulation. 2017. PMID: 28137963 Free PMC article.
Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis.
Flores AM, Hosseini-Nassab N, Jarr KU, Ye J, Zhu X, Wirka R, Koh AL, Tsantilas P, Wang Y, Nanda V, Kojima Y, Zeng Y, Lotfi M, Sinclair R, Weissman IL, Ingelsson E, Smith BR, Leeper NJ. Flores AM, et al. Among authors: kojima y. Nat Nanotechnol. 2020 Feb;15(2):154-161. doi: 10.1038/s41565-019-0619-3. Epub 2020 Jan 27. Nat Nanotechnol. 2020. PMID: 31988506 Free PMC article.
The pleiotropic benefits of statins include the ability to reduce CD47 and amplify the effect of pro-efferocytic therapies in atherosclerosis.
Jarr KU, Ye J, Kojima Y, Ye Z, Gao H, Schmid S, Luo L, Baylis RA, Lotfi M, Lopez N, Eberhard AV, Smith BR, Weissman IL, Maegdefessel L, Leeper NJ. Jarr KU, et al. Among authors: kojima y. Nat Cardiovasc Res. 2022 Mar;1(3):253-262. doi: 10.1038/s44161-022-00023-x. Epub 2022 Mar 7. Nat Cardiovasc Res. 2022. PMID: 35990913 Free PMC article.
Macrophage LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) Is Required for the Effect of CD47 Blockade on Efferocytosis and Atherogenesis-Brief Report.
Mueller PA, Kojima Y, Huynh KT, Maldonado RA, Ye J, Tavori H, Pamir N, Leeper NJ, Fazio S. Mueller PA, et al. Among authors: kojima y. Arterioscler Thromb Vasc Biol. 2022 Jan;42(1):e1-e9. doi: 10.1161/ATVBAHA.121.316854. Epub 2021 Nov 11. Arterioscler Thromb Vasc Biol. 2022. PMID: 34758632 Free PMC article.
Clonally expanding smooth muscle cells promote atherosclerosis by escaping efferocytosis and activating the complement cascade.
Wang Y, Nanda V, Direnzo D, Ye J, Xiao S, Kojima Y, Howe KL, Jarr KU, Flores AM, Tsantilas P, Tsao N, Rao A, Newman AAC, Eberhard AV, Priest JR, Ruusalepp A, Pasterkamp G, Maegdefessel L, Miller CL, Lind L, Koplev S, Björkegren JLM, Owens GK, Ingelsson E, Weissman IL, Leeper NJ. Wang Y, et al. Among authors: kojima y. Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):15818-15826. doi: 10.1073/pnas.2006348117. Epub 2020 Jun 15. Proc Natl Acad Sci U S A. 2020. PMID: 32541024 Free PMC article.
Effect of CD47 Blockade on Vascular Inflammation.
Jarr KU, Nakamoto R, Doan BH, Kojima Y, Weissman IL, Advani RH, Iagaru A, Leeper NJ. Jarr KU, et al. Among authors: kojima y. N Engl J Med. 2021 Jan 28;384(4):382-383. doi: 10.1056/NEJMc2029834. N Engl J Med. 2021. PMID: 33503349 Free PMC article. No abstract available.
2,191 results